Compounds represented by the general formula (I): ##STR00001## wherein Ar.sup.1 and Ar.sup.2 are each aryl or heteroaryl; R.sup.1 is lower cycloalkyl, --Ar.sup.3, or a group of the general formula (a), (b) or (c): ##STR00002## and R.sup.2 and R.sup.3are each hydrogen, lower cycloalkyl, lower alkenyl, or optionally substituted lower alkyl (with the proviso that when R.sup.2 and R.sup.3 are simultaneously hydrogen, Ar.sup.1, Ar.sup.2 and R.sup.1 do not simultaneously represent unsubstituted phenyl). The compounds are useful as treating agents for various NPY-related diseases, for example, circulatory diseases including hypertension, kidney diseases, cardiac diseases, vasospasm and arteriosclerosis; central nervous system diseases including hyperphagia, depression, anxiety, convulsion, epilepsy, dementia, pain, alcohol dependence, and withdrawal symptoms due to abstinence from drugs; metabolic diseases including obesity, diabetes, hormonal disorders, hypercholesterolemia, and hyperlipidemia; sexual dysfunction and reproductive function disorders; digestive diseases including enterokinetic disorders; respiratory diseases; inflammation; or glaucoma.

Banyu Pharmaceutical Co., Ltd.

Imidazoline compounds

Compounds represented by the general formula (I): ##STR00001## wherein Ar.sup.1 and Ar.sup.2 are each aryl or heteroaryl; R.sup.1 is lower cycloalkyl, --Ar.sup.3, or a group of the general formula (a), (b) or (c): ##STR00002## and R.sup.2 and R.sup.3 are each hydrogen, lower cycloalkyl, lower alkenyl, or optionally substituted lower alkyl (with the proviso that when R.sup.2 and R.sup.3 are simultaneously hydrogen, Ar.sup.1, Ar.sup.2 and R.sup.1 do not simultaneously represent unsubstituted phenyl). The compounds are useful as treating agents for various NPY-related diseases, for example, circulatory diseases including hypertension, kidney diseases, cardiac diseases, vasospasm and arteriosclerosis; central nervous system diseases including hyperphagia, depression, anxiety, convulsion, epilepsy, dementia, pain, alcohol dependence, and withdrawal symptoms due to abstinence from drugs; metabolic diseases including obesity, diabetes, hormonal disorders, hypercholesterolemia, and hyperlipidemia; sexual dysfunction and reproductive function disorders; digestive diseases including enterokinetic disorders; respiratory diseases; inflammation; or glaucoma.

Banyu Pharmaceutical, Co., Ltd.

Imidazonline compounds

Compounds of the formula (I): ##STR00001## (wherein A is an optionally substituted straight-chain hydrocarbon having 1 to 6 carbon atoms, which is optionally intervened by oxygen or nitrogen atom; Ar.sup.1 is aryl or heteroaryl, any of which is optionally substituted; n is 0 or 1; R.sup.0 is hydrogen, or lower alkylene attached to an arbitrary, bondable position of A; T, U, V and W are independently nitrogen atom or optionally substituted methine, and at least two of T, U, V and W are said methine group; X is --N(SO.sub.2R.sup.1)--, --N(COR.sup.2)-- or --CO--; Y is --C(R.sup.3)(R.sup.4)--, --O-- or --N(R.sup.5)--; Z is methine or nitrogen atom) exhibit NPY antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders such as hypertension, nephropathy, heart disease, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, etc., sexual and reproductive dysfunctions, and gastro-intestinal motility disorder.

hypercholesterolemia/seizures

Imidazoline compounds

Imidazonline compounds

Spiro compounds

La base de dades d’herbes medicinals més completa avalada per la ciència